FDA Hands IBSA Farmaceutici 483 Over CAPAs, Procedures

IBSA Farmaceutici did not open a corrective action, as required, for a trend in adverse events involving pain and/or swelling in the knee following injection of Sinovial or other sodium hyaluronate devices, according to a Form 483.
The GMP Letter